Overview
Quanterix Q2 2025 revenue falls 29% yr/yr, net loss widens significantly
Company completed acquisition of Akoya Biosciences, aiming for cash flow breakeven by 2026
Alzheimer's Diagnostics revenues more than tripled yr/yr, despite market challenges
Outlook
Quanterix expects full-year 2025 revenue between $130 mln and $135 mln
Quanterix projects GAAP gross margin of 49% to 53% for 2025
Company aims for cash flow breakeven in 2026
Result Drivers
AKOYA COMBINATION - Quanterix cites combination with Akoya Biosciences as creating high-margin, high-throughput business
ALZHEIMER'S DIAGNOSTICS - Alzheimer's Diagnostics revenues more than tripled yr/yr, indicating strong demand
ACCELERATOR BUSINESS - Net increase in new customers despite smaller project sizes due to constrained biopharma budgets
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue | $16.83 mln | ||
Q2 Net Income | -$30.01 mln | ||
Q2 Basic EPS | -$0.77 | ||
Q2 Gross Profit | $11.30 mln | ||
Q2 Operating Expenses | $48.40 mln | ||
Q2 Operating Income | -$37.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corp is $8.00, about 29.9% above its August 6 closing price of $5.61
Press Release: ID:nBw2nmH8Ra
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)